Correlation between serum tryptase, mast cells positive to tryptase and microvascular density in colo-rectal cancer patients

Possible biological-clinical significance

Michele Ammendola, Rosario Sacco, Giuseppe Sammarco, Giuseppe Donato, Severino Montemurro, Eustachio Ruggieri, Rosa Patruno, Ilaria Marech, Marica Cariello, Angelo Vacca, Cosmo Damiano Gadaleta, Girolamo Ranieri

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Tryptase is a serin protease stored and released from mast cells (MCs) that plays a role in tumour angiogenesis. In this study we aimed to evaluate serum tryptase levels in colo-rectal cancer (CRC) patients before (STLBS) and after (STLAS) radical surgical resection. We also evaluated mast cell density positive to tryptase (MCDPT) and microvascular density (MVD) in primary tumour tissue. Methods: A series of 61 patients with stage B and C CRC (according to the Astler and Coller staging system) were selected. Serum blood samples were collected from patients one day before and one day after surgery. Tryptase levels were measured using the UniCAP Tryptase Fluoroenzymeimmunoassay (Pharmacia, Uppsala, Sweden). Tumour sections were immunostained with a primary anti-tryptase antibody (clone AA1; Dako, Glostrup, Denmark) and an anti CD-34 antibody (QB-END 10; Bio-Optica Milan, Italy) by means of immunohistochemistry and then evaluated by image analysis methods. Results: The mean ± s.d. STLBS and STLAS was 5.63±2.61 μg/L, and 3.39±1.47 μg/L respectively and a significant difference between mean levels was found: p = 0.000 by t-test. The mean ± s.d. of MCDPT and MVD was 8.13±3.28 and 29.16±7.39 respectively. A strong correlation between STLBS and MVD (r = 0.83, p = 0.000); STLBS and MCDPT (r = 0.60, p = 0.003); and MCDPT and MVD (r = 0.73; p = 0.001) was found. Conclusion: Results demonstrated higher STLBS in CRC patients, indicating an involvement of MC tryptase in CRC angiogenesis. Data also indicated lower STLAS, suggesting the release of tryptase from tumour-infiltrating MCs. Serum tryptase levels may therefore play a role as a novel bio-marker predictive of response to radical surgery. In this context tryptase inhibitors such as Gabexate and Nafamostat Mesilate might be evaluated in adjuvant clinical trials as a new antiangiogenic approach.

Original languageEnglish
Article numbere99512
JournalPLoS One
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 10 2014

Fingerprint

tryptase
Tryptases
plasmin
mast cells
Rectal Neoplasms
colorectal neoplasms
Serum
Mast Cells
Tumors
Cell Count
angiogenesis
neoplasms
Surgery
surgery
Neoplasms
Gabexate
antibodies
resection
blood serum
Antibodies

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Correlation between serum tryptase, mast cells positive to tryptase and microvascular density in colo-rectal cancer patients : Possible biological-clinical significance. / Ammendola, Michele; Sacco, Rosario; Sammarco, Giuseppe; Donato, Giuseppe; Montemurro, Severino; Ruggieri, Eustachio; Patruno, Rosa; Marech, Ilaria; Cariello, Marica; Vacca, Angelo; Gadaleta, Cosmo Damiano; Ranieri, Girolamo.

In: PLoS One, Vol. 9, No. 6, e99512, 10.06.2014.

Research output: Contribution to journalArticle

Ammendola, Michele ; Sacco, Rosario ; Sammarco, Giuseppe ; Donato, Giuseppe ; Montemurro, Severino ; Ruggieri, Eustachio ; Patruno, Rosa ; Marech, Ilaria ; Cariello, Marica ; Vacca, Angelo ; Gadaleta, Cosmo Damiano ; Ranieri, Girolamo. / Correlation between serum tryptase, mast cells positive to tryptase and microvascular density in colo-rectal cancer patients : Possible biological-clinical significance. In: PLoS One. 2014 ; Vol. 9, No. 6.
@article{90bd6d53c8a744bca0ddf4eb26d92397,
title = "Correlation between serum tryptase, mast cells positive to tryptase and microvascular density in colo-rectal cancer patients: Possible biological-clinical significance",
abstract = "Background: Tryptase is a serin protease stored and released from mast cells (MCs) that plays a role in tumour angiogenesis. In this study we aimed to evaluate serum tryptase levels in colo-rectal cancer (CRC) patients before (STLBS) and after (STLAS) radical surgical resection. We also evaluated mast cell density positive to tryptase (MCDPT) and microvascular density (MVD) in primary tumour tissue. Methods: A series of 61 patients with stage B and C CRC (according to the Astler and Coller staging system) were selected. Serum blood samples were collected from patients one day before and one day after surgery. Tryptase levels were measured using the UniCAP Tryptase Fluoroenzymeimmunoassay (Pharmacia, Uppsala, Sweden). Tumour sections were immunostained with a primary anti-tryptase antibody (clone AA1; Dako, Glostrup, Denmark) and an anti CD-34 antibody (QB-END 10; Bio-Optica Milan, Italy) by means of immunohistochemistry and then evaluated by image analysis methods. Results: The mean ± s.d. STLBS and STLAS was 5.63±2.61 μg/L, and 3.39±1.47 μg/L respectively and a significant difference between mean levels was found: p = 0.000 by t-test. The mean ± s.d. of MCDPT and MVD was 8.13±3.28 and 29.16±7.39 respectively. A strong correlation between STLBS and MVD (r = 0.83, p = 0.000); STLBS and MCDPT (r = 0.60, p = 0.003); and MCDPT and MVD (r = 0.73; p = 0.001) was found. Conclusion: Results demonstrated higher STLBS in CRC patients, indicating an involvement of MC tryptase in CRC angiogenesis. Data also indicated lower STLAS, suggesting the release of tryptase from tumour-infiltrating MCs. Serum tryptase levels may therefore play a role as a novel bio-marker predictive of response to radical surgery. In this context tryptase inhibitors such as Gabexate and Nafamostat Mesilate might be evaluated in adjuvant clinical trials as a new antiangiogenic approach.",
author = "Michele Ammendola and Rosario Sacco and Giuseppe Sammarco and Giuseppe Donato and Severino Montemurro and Eustachio Ruggieri and Rosa Patruno and Ilaria Marech and Marica Cariello and Angelo Vacca and Gadaleta, {Cosmo Damiano} and Girolamo Ranieri",
year = "2014",
month = "6",
day = "10",
doi = "10.1371/journal.pone.0099512",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Correlation between serum tryptase, mast cells positive to tryptase and microvascular density in colo-rectal cancer patients

T2 - Possible biological-clinical significance

AU - Ammendola, Michele

AU - Sacco, Rosario

AU - Sammarco, Giuseppe

AU - Donato, Giuseppe

AU - Montemurro, Severino

AU - Ruggieri, Eustachio

AU - Patruno, Rosa

AU - Marech, Ilaria

AU - Cariello, Marica

AU - Vacca, Angelo

AU - Gadaleta, Cosmo Damiano

AU - Ranieri, Girolamo

PY - 2014/6/10

Y1 - 2014/6/10

N2 - Background: Tryptase is a serin protease stored and released from mast cells (MCs) that plays a role in tumour angiogenesis. In this study we aimed to evaluate serum tryptase levels in colo-rectal cancer (CRC) patients before (STLBS) and after (STLAS) radical surgical resection. We also evaluated mast cell density positive to tryptase (MCDPT) and microvascular density (MVD) in primary tumour tissue. Methods: A series of 61 patients with stage B and C CRC (according to the Astler and Coller staging system) were selected. Serum blood samples were collected from patients one day before and one day after surgery. Tryptase levels were measured using the UniCAP Tryptase Fluoroenzymeimmunoassay (Pharmacia, Uppsala, Sweden). Tumour sections were immunostained with a primary anti-tryptase antibody (clone AA1; Dako, Glostrup, Denmark) and an anti CD-34 antibody (QB-END 10; Bio-Optica Milan, Italy) by means of immunohistochemistry and then evaluated by image analysis methods. Results: The mean ± s.d. STLBS and STLAS was 5.63±2.61 μg/L, and 3.39±1.47 μg/L respectively and a significant difference between mean levels was found: p = 0.000 by t-test. The mean ± s.d. of MCDPT and MVD was 8.13±3.28 and 29.16±7.39 respectively. A strong correlation between STLBS and MVD (r = 0.83, p = 0.000); STLBS and MCDPT (r = 0.60, p = 0.003); and MCDPT and MVD (r = 0.73; p = 0.001) was found. Conclusion: Results demonstrated higher STLBS in CRC patients, indicating an involvement of MC tryptase in CRC angiogenesis. Data also indicated lower STLAS, suggesting the release of tryptase from tumour-infiltrating MCs. Serum tryptase levels may therefore play a role as a novel bio-marker predictive of response to radical surgery. In this context tryptase inhibitors such as Gabexate and Nafamostat Mesilate might be evaluated in adjuvant clinical trials as a new antiangiogenic approach.

AB - Background: Tryptase is a serin protease stored and released from mast cells (MCs) that plays a role in tumour angiogenesis. In this study we aimed to evaluate serum tryptase levels in colo-rectal cancer (CRC) patients before (STLBS) and after (STLAS) radical surgical resection. We also evaluated mast cell density positive to tryptase (MCDPT) and microvascular density (MVD) in primary tumour tissue. Methods: A series of 61 patients with stage B and C CRC (according to the Astler and Coller staging system) were selected. Serum blood samples were collected from patients one day before and one day after surgery. Tryptase levels were measured using the UniCAP Tryptase Fluoroenzymeimmunoassay (Pharmacia, Uppsala, Sweden). Tumour sections were immunostained with a primary anti-tryptase antibody (clone AA1; Dako, Glostrup, Denmark) and an anti CD-34 antibody (QB-END 10; Bio-Optica Milan, Italy) by means of immunohistochemistry and then evaluated by image analysis methods. Results: The mean ± s.d. STLBS and STLAS was 5.63±2.61 μg/L, and 3.39±1.47 μg/L respectively and a significant difference between mean levels was found: p = 0.000 by t-test. The mean ± s.d. of MCDPT and MVD was 8.13±3.28 and 29.16±7.39 respectively. A strong correlation between STLBS and MVD (r = 0.83, p = 0.000); STLBS and MCDPT (r = 0.60, p = 0.003); and MCDPT and MVD (r = 0.73; p = 0.001) was found. Conclusion: Results demonstrated higher STLBS in CRC patients, indicating an involvement of MC tryptase in CRC angiogenesis. Data also indicated lower STLAS, suggesting the release of tryptase from tumour-infiltrating MCs. Serum tryptase levels may therefore play a role as a novel bio-marker predictive of response to radical surgery. In this context tryptase inhibitors such as Gabexate and Nafamostat Mesilate might be evaluated in adjuvant clinical trials as a new antiangiogenic approach.

UR - http://www.scopus.com/inward/record.url?scp=84902603135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902603135&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0099512

DO - 10.1371/journal.pone.0099512

M3 - Article

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e99512

ER -